Adverse events108

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

101 to 108 of 108

Type	Event	Organ system	Group	Affected	At risk	Events
serious	Colitis	Gastrointestinal disorders	INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID	1	10	1
serious	Colitis	Gastrointestinal disorders	Total	1	10	1
serious	Myelodysplastic syndrome	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID	1	10	1
serious	Myelodysplastic syndrome	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Total	1	10	1
serious	Rectal haemorrhage	Gastrointestinal disorders	INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID	1	10	1
serious	Rectal haemorrhage	Gastrointestinal disorders	Total	1	10	1
serious	Uveitis	Eye disorders	INCAGN01876 300 mg Q3W + Pembrolizumab 200 mg Q3W + Epacadostat 100 mg BID	1	10	1
serious	Uveitis	Eye disorders	Total	1	10	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03277352/events?page=6